Pharmaceuticals

Nivolumab Market Insights Highlighting Opportunities Supporting Growth To 2030

May 1, 2026May 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Nivolumab Market During 2026–2030?

The nivolumab market size has experienced rapid expansion in recent years. This market is projected to expand from $1.92 billion in 2025 to $2.17 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.9%. The historic growth can be primarily linked to several factors, including the increasing occurrence of melanoma and nsclc, the early authorization of nivolumab for metastatic cancers, the expansion of hospital facilities for oncology care, a surge in oncology research and clinical trials, and the wider acceptance of monoclonal antibody treatments.

The nivolumab market size is anticipated to undergo significant expansion over the next few years, projected to achieve $3.63 billion by 2030 at a compound annual growth rate (CAGR) of 13.8%. This growth during the forecast period can be ascribed to factors such as the broadening of nivolumab indications, an increase in the elderly cancer population, its integration with combination therapies, heightened investment in biologics manufacturing, and the development of oncology infrastructure in emerging markets. Noteworthy trends for this period include advancements in immuno-oncology, the evolution of combination therapy, personalized cancer treatment strategies, the expansion of hospital-based oncology provisions, and a growing embrace of targeted therapies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13012&type=smp

What Primary Drivers Are Shaping The Nivolumab Market?

The increasing occurrence of non-small cell lung cancer (NSCLC) is projected to boost the Nivolumab market’s expansion in the foreseeable future. Non-small cell lung cancer (NSCLC) is a type of lung cancer that develops from the lungs’ epithelial cells. Nivolumab is an approved medication prescribed for patients with advanced non-small cell lung cancer (NSCLC), owing to its demonstrated effectiveness in treating the condition. For example, in March 2023, the American Society of Clinical Oncology, a US-based professional organization representing oncologists, reported an anticipated 238,340 people (consisting of 117,550 men and 120,790 women) would be diagnosed with lung cancer in the United States. Of these cases, NSCLC is the predominant form, accounting for 81% of all lung cancer diagnoses. Therefore, the rising incidence of non-small cell lung cancer (NSCLC) is a key factor driving the Nivolumab market.

How Is The Nivolumab Market Broken Down By Segment Categories?

The nivolumab market covered in this report is segmented –

1) By Type: Injection 4mL, Injection 10mL

2) By Route Of Administration: Intravenous, Other Routes Of Administration

3) By Application: Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications

4) By End-User: Clinic, Hospital, Other End-Users

What Trends Are Affecting The Growth Of The Nivolumab Market?

Leading companies in the nivolumab market are prioritizing the development of new formulations and the expansion of treatment indications to enhance patient convenience and strengthen their immuno-oncology portfolios. For example, in December 2024, the Food and Drug Administration, a federal agency based in the US, approved Opdivo Qvantig, a subcutaneous formulation of nivolumab combined with hyaluronidase-nvhy, for use across all adult solid-tumor indications previously approved for intravenous nivolumab. This novel option supports monotherapy, maintenance therapy following Opdivo plus Yervoy, or combination treatment with chemotherapy or cabozantinib. The approval is substantiated by the Phase 3 CHECKMATE-67T trial, which indicated comparable drug exposure, similar safety, and a slightly higher response rate than IV nivolumab in advanced renal cell carcinoma patients. With its flexible dosing schedules and sustained efficacy, the subcutaneous version provides a more convenient alternative for patients and bolsters Bristol Myers Squibb’s immuno-oncology portfolio.

Which Players Are Present In The Nivolumab Market Space?

Major companies operating in the nivolumab market are Bristol-Myers Squibb Company, Ono Pharmaceutical Co. Ltd., Xbrane Biopharma AB, NeuClone Therapeutics Inc., Dr. Reddy’s Laboratories Ltd., Biocon Limited, Samsung Bioepis Co. Ltd., Celltrion Inc., Amneal Pharmaceuticals LLC, Lupin Ltd., Intas Pharmaceuticals Ltd., Hetero Biopharma Ltd., Reliance Life Sciences Pvt. Ltd., Zydus Lifesciences Limited, mAbxience, Shanghai Henlius Biotech Inc., Innovent Biologics Inc., WuXi Biologics, Lonza Group AG, Samsung Biologics

Get The Full Nivolumab Market Report:

https://www.thebusinessresearchcompany.com/report/nivolumab-global-market-report

Which Region Has The Greatest Market Share In The Nivolumab Market?

North America was the largest region in the nivolumab market in 2025. The regions covered in the nivolumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Nivolumab Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/nivolumab-global-market-report

Browse Through More Reports Similar to the Global Nivolumab Market 2026, By The Business Research Company

Nivolumab Market Report 2026

https://www.thebusinessresearchcompany.com/report/nivolumab-global-market-report

Nitric Acid Market Report 2026

https://www.thebusinessresearchcompany.com/report/nitric-acid-global-market-report

Nitrobenzene Market Report 2026

https://www.thebusinessresearchcompany.com/report/nitrobenzene-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795